Your cart is empty.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Männedorf, Switzerland, September 15, 2010 - The Tecan Group (SIX Swiss Exchange:TECN) today announced that it will present at the UBS Global Life Sciences Conference onTuesday, September 21, 2010 in New York City.The investor presentation by Thomas Bachmann, CEO of the Tecan Group, will begin at 12:00p.m. EDT (6:00 p.m. CET). The presentation will be webcast live and may be accessed underthe “Investor Relations” tab of Tecan’s website www.tecan.com.A replay of the webcast will be available shortly following the presentation and will remainavailable for at least four weeks.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).
For further information please contact:
Martin Braendle T +41 (0) 44 922 84 30 |
Downloads: